EGFR and non-small cell lung carcinoma: So, this study aims to comprehensively review and evaluate the therapeutic potential of anlotinib in the treatment of advanced NSCLC, with a particular focus on its efficacy as a monotherapy and in combination with various treatment modalities, including chemotherapy, radiotherapy, EGFR-TKIs, and immunotherapy.